SNY and REGN Related Headlines
Go Back- Regeneron beats first quarter estimates on Dupixent strength
- Goldman Sachs sees nearly 140% upside in this biopharma stock
- BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
- Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
